Latest news with #ObstructivePulmonary
Yahoo
19-05-2025
- Health
- Yahoo
Chronic Obstructive Pulmonary Disease (COPD) Seven-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033
Explore the future of the Chronic Obstructive Pulmonary Disease (COPD) market with our comprehensive report. This forecast model covers the 7 major markets from 2023 to 2033, predicting a CAGR of 10%, growing from $11.6 billion in 2023 to $30.2 billion by 2033. Discover market insights, pipeline analysis, and strategies for effective competitiveness in the 7MM COPD therapeutics landscape. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD): Seven-Market Drug Forecast and Market Analysis - Update (2025)" has been added to offering. This comprehensive report provides an in-depth analysis of the Chronic Obstructive Pulmonary Disease (COPD) market across seven major markets, featuring an Excel-based model forecasting market trends through 2033. COPD, a progressive lung disease, continues to present significant health challenges globally. Our analysis investigates this market's path over the next decade, beginning with an estimated value of $11.6 billion in 2023 and projecting growth to $30.2 billion by 2033, reflecting a compound annual growth rate (CAGR) of 10.0%. Our forecast encompasses both currently marketed and pipeline drugs tailored for COPD, with 2023 as the base year. Key deliverables include a detailed PDF report along with an Excel-based model providing intricate market forecasts. Key Highlights Forecasting tools offered include a PDF report and an Excel-based model. The 7MM serves as the focal point for our projections spanning 2023 to 2033. Scope Provides a detailed overview of COPD, addressing epidemiology, symptoms, diagnosis, disease management, and the Asthma-COPD Overlap (ACO). Includes annualized market revenue data, per patient therapy costs, and treatment usage forecasts for the period 2023-2033. Covers strategic competitor assessments, market dynamics, unmet needs, clinical trials, and their collective impacts on COPD therapeutics. Features pipeline analysis, presenting data on emerging therapeutic trends and development mechanisms, highlighting promising late-stage candidates. Presents a competitive analysis of the global COPD market, exploring industry drivers, barriers, and challenges. Key Topics Covered: Chronic Obstructive Pulmonary Disease: Executive Summary Introduction Disease Overview Epidemiology Disease Management Current Treatment Options Unmet Needs and Opportunity Assessment R&D Strategies Pipeline Assessment Pipeline Valuation Analysis Current and Future Players Market Outlook Appendix About the Analyst Contact the Publisher Companies Featured Sanofi Regeneron GSK AstraZeneca Verona Pharma Chiesi Pharma Roche Genentech Boehringer Ingelheim Theravance Biopharma Novartis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Winnipeg Free Press
30-04-2025
- Politics
- Winnipeg Free Press
First Nations people rally for housing as class action suit heard in Winnipeg
About 100 people rallied downtown as a class action lawsuit that accuses the federal government of failing to address the housing crisis on First Nations was front and centre in a Winnipeg courtroom Wednesday. 'Some of the houses are deplorable, they're not livable, and a lot of our people, they have no choice but to live there,' said St. Theresa Point First Nation Chief Raymond Flett outside the Anishininew Okimawin building on Broadway. St. Theresa Point First Nation in Manitoba and Sandy Lake First Nation in northwest Ontario filed the suit in 2023. More than 100 First Nations have signed on. The case is being heard this week in federal court. The suit seeks $5 billion in damages. ALEX LAMBERT / FREE PRESS Rally participant Chloe Kakepetum (left) hugs Myrna Mawakeesic, who says she developed Chronic Obstructive Pulmonary Disease because of the constant flooding her house gets every spring in Sandy Lake, Ont. The rally, in support of a lawsuit against the federal government, was at Anishininew Okimawin on Broadway. Flett said Ottawa has failed to provide adequate housing on First Nations. 'A house, even though it's not that old, but the material used to build that house is cheap material — they don't last,' said Flett. 'Most of the houses only have two or three bedrooms… that is not right for us, a lot of families they have four adults, five children living in a house.' He said its hard for residents to maintain houses in small communities because of the lack of resources. 'You have a broken door and want to fix it? We can't just go to the store and buy it,' Flett said. 'You have to fly it in, and that's extra, a lot of extra money that we don't have.' Former St. Theresa Point chief Elvin Flett, and Toronto-based firm McCarthy Tétrault LLP filed a statement of claim in June 2023 that alleged Canada 'deliberately underfunded housing on reserves,' while simultaneously isolating First Nations by imposing restrictions on their ability to provide housing for themselves. 'They're the ones that put us in there in the first place, they have to honour that,' said Raymond Flett. The chief wants to see an equal partnership with the Canadian government to improve housing and development. Flett said he is hopeful it will happen. The statement of claim said of the 646 houses in St. Theresa Point, 25 per cent should be condemned due to severe decay and rotting. It also said more than half of the houses in Sandy Lake require major repairs. One woman from Sandy Lake said she developed chronic obstructive pulmonary disease because of the poor condition her house is in. She said she has had trouble breathing for years because her house floods every spring. 'We want our kids to have better housing than what we have right now,' said Myrna Mawakeesic, 57, who was also part of the rally. During Elections Get campaign news, insight, analysis and commentary delivered to your inbox during Canada's 2025 election. Another rallygoer said she wanted to help make a difference. 'Monkey see monkey do, when you see someone fighting for something that they like, then you'll get inspired by something you like,' said 18-year-old Kariya Kakepetum, who is also from Sandy Lake. 'What I love is my community.' Canada argued in its 2024 statement of defence the country 'does not owe any legal obligations or duties to build and maintain houses on-reserve. The claim should be dismissed.' St. Theresa Point, 465 kilometres northeast of Winnipeg, is one of four First Nations that make up the Island Lake region in northeastern Manitoba. The community of 5,200 people is accessible by plane or ice road for six weeks out of the year. fpcity@
Yahoo
17-02-2025
- Business
- Yahoo
Pneuma Respiratory Advances Inhaled Therapeutics to Improve Respiratory Health
Starting with Reduced-Risk NicotineExpanding in Chronic Obstructive Pulmonary Disease and Other Therapeutic Areas BOONE, N.C., February 17, 2025--(BUSINESS WIRE)--Pneuma Respiratory, a med-tech and pharmaceutical company dedicated to advancing inhaled respiratory therapeutics, is introducing new transformational approaches to respiratory health to improve the standard of care for millions of patients worldwide. Focusing on treatments for smoking-related lung conditions, Pneuma has developed a novel aerosol generation technology that provides a more efficient way to deliver medication to the lungs. Pneuma is accelerating its goal to improve respiratory health through the creation of strategic partnerships, aiming to rapidly deliver new solutions, at-scale, in the reduced-risk nicotine field. In addition, Pneuma has programs in developing treatments for conditions like chronic obstructive pulmonary disease (COPD), non-small cell lung cancer, and precancerous conditions. With 54 issued patents and over 100 pending applications, the company is actively securing its leadership in the field. Its breakthrough technology offers significant harm reduction opportunities in inhaled nicotine, while also demonstrating promising applications for respiratory treatments. Disrupting the Market with Next-Generation Technology For reduced-risk nicotine applications, Pneuma's technology offers the benefits of: Non-Heated Technology – Avoids thermal degradation byproducts such as formaldehyde, acetaldehyde, and benzene, providing a cleaner, less harmful nicotine delivery. Water-Based Solutions – Offers a more natural alternative to traditional inhalation methods, eliminating unnecessary chemical additives. Reduced Secondhand Nicotine Exposure – Designed to minimize the impact of nicotine on non-users. For pharmaceutical applications, Pneuma's technology offers the benefits of: Ultra-Fine Droplet Precision – Precision control over sub-micron aerosol droplet size, allowing targeted delivery to different regions of the lung. High Respirable Fractions – Exceeds 90% aerosol delivery to the lungs, thereby reducing the systemic dose required to achieve a given therapeutic effect. Fully Digital Breath-Actuated Delivery – Seamlessly delivers medications as patients breathe, improving ease of use, adherence, and comfort. Partnerships and Licensing to Address Global Market Opportunities Pneuma is prioritizing the reduced-risk nicotine market for its initial go-to-market strategy, aiming for the greatest global health impact while addressing a significant market opportunity. By accelerating the adoption of its life-saving technologies, the company has the potential to help move the world toward a smokeless future and save hundreds of millions of lives. To fast-track availability, Pneuma is partnering with global strategic partners in the reduced-risk nicotine product space, along with major healthcare and pharmaceutical companies in therapeutic areas. "Our goal is to bring better treatment options to people who need them most," said Eric Hunter, CEO and Co-Founder of Pneuma Respiratory. "Over the last year, we have significantly expanded our patent portfolio, refined our device and app designs, and strengthened our industry partnerships. We are committed to making a lasting impact on respiratory health." Impact on Global Health Pneuma is preparing to release pivotal third-party study results that demonstrate the effectiveness of its non-heated reduced-risk nicotine product, including its ability to reduce harmful compounds and secondhand nicotine exposure. Beyond nicotine-related conditions, Pneuma's inhaled therapeutics have broad potential in treating other lung diseases. With its fully digital technology, the company aims to improve treatment effectiveness while minimizing side effects. For more information, visit View source version on Contacts Media Contact: Caley ModlinPneuma Respiratory,
